Revenue and Profit - Revenue for Q3 2021 was CNY 83,091,191.37, a decrease of 12.96% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 3,329,275.88, down 86.08% year-on-year[4] - Net profit excluding non-recurring gains and losses increased by 33.54% to CNY 2,729,348.01[4] - Basic earnings per share decreased by 86.67% to CNY 0.004[5] - Total operating revenue for the first three quarters of 2021 reached ¥261,489,542.54, an increase from ¥251,919,577.93 in the same period of 2020, representing a growth of approximately 3.5%[19] - Net profit for the third quarter of 2021 was ¥27,449,953.98, down from ¥57,422,437.31 in the same quarter of 2020, reflecting a decline of approximately 52.2%[20] - The comprehensive income total for the third quarter of 2021 was ¥28,666,043.89, down from ¥59,877,397.08 in the same quarter of 2020, reflecting a decline of about 52.1%[21] - Basic earnings per share for the third quarter of 2021 were ¥0.030, down from ¥0.070 in the same quarter of 2020, reflecting a decrease of approximately 57.1%[21] Assets and Liabilities - Total assets increased by 5.90% to CNY 1,370,284,431.99 compared to the end of the previous year[5] - The company's total liabilities as of the third quarter of 2021 amounted to ¥471,269,524.81, an increase from ¥421,332,215.02 in the previous year, showing a rise of about 11.9%[18] - The total assets as of Q3 2021 were CNY 1,293,961,078.31, reflecting a decrease from CNY 1,432,862,354.87 at the beginning of the year[28] - The company’s total liabilities decreased to CNY 1,022,196,636.45 from CNY 1,161,097,913.01 at the start of the year[28] - Total liabilities amounted to ¥421,332,215.02, a decrease of ¥138,901,276.56 compared to the previous period[29] - Current liabilities totaled ¥246,260,471.39, while non-current liabilities were ¥175,071,743.63[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,493[11] - The largest shareholder, Dazhong Transportation Group, holds 16.37% of shares[11] - Shanghai Xinnanyang Angli Education Technology Co., Ltd. is the second-largest shareholder with a 13.53% stake[11] - The total equity attributable to shareholders reached ¥860,906,742.64, compared to ¥834,900,061.69 in the same period last year, marking an increase of approximately 3.1%[18] Cash Flow - Cash flow from operating activities increased by 67.59% to CNY 59,767,073.49 year-to-date[4] - Cash flow from operating activities for the first three quarters of 2021 was ¥266,397,229.75, compared to ¥246,752,497.20 in 2020, representing an increase of about 7.9%[23] - Net cash flow from operating activities for Q3 2021 was CNY 59,767,073.49, an increase of 67.5% compared to CNY 35,663,404.09 in Q3 2020[24] - Total cash inflow from investment activities was CNY 10,857,624.99, a decrease of 80.6% from CNY 55,913,541.19 in the previous year[24] - Cash flow from financing activities showed a net outflow of CNY 54,001,226.48, compared to a net outflow of CNY 129,196,439.61 in Q3 2020[25] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥239,402,966.95, compared to ¥221,565,183.14 in 2020, indicating an increase of about 8.0%[19] - Research and development expenses for the first three quarters of 2021 were ¥10,498,101.06, up from ¥8,316,124.31 in 2020, indicating a growth of about 26.3%[19] Strategic Relationships - The company has established a strategic relationship with its major shareholders, indicating potential for future collaboration and market expansion[13]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥178,398,351.17, representing a 14.03% increase compared to ¥156,449,097.57 in the same period last year[18]. - The net profit attributable to shareholders decreased by 33.33% to ¥20,424,555.96 from ¥30,635,518.42 year-on-year[18]. - The net profit after deducting non-recurring gains and losses increased by 57.64% to ¥16,289,819.66 compared to ¥10,333,409.12 in the previous year[18]. - The net cash flow from operating activities rose by 58.80% to ¥39,080,452.35 from ¥24,610,520.33 in the same period last year[18]. - Basic earnings per share decreased by 33.33% to ¥0.026 from ¥0.039 in the same period last year[19]. - The total comprehensive income for the first half of 2021 was ¥24,344,292.52, compared to ¥30,538,533.62 in the same period of 2020, a decrease of 20.3%[93]. - The company reported a net loss of CNY 111,154,081.94, improving from a loss of CNY 131,578,637.90 in the previous period[85]. - The company reported a total comprehensive income loss of CNY 1,905,988.20 during the current period, indicating a significant decline compared to the previous period[114]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,326,239,362.81, a 2.49% increase from ¥1,293,961,078.31 at the end of the previous year[18]. - Total liabilities amounted to CNY 431,546,207.00, slightly up from CNY 421,332,215.02, indicating a growth of 2.9%[85]. - Current assets totaled CNY 251,156,922.33, a decrease of 7.6% from CNY 271,764,441.86 at the end of 2020[84]. - Cash and cash equivalents decreased to CNY 86,402,028.05 from CNY 118,012,055.66, a decline of 26.9%[83]. - Total equity attributable to shareholders was CNY 834,900,061.69 at the beginning of the year, with a total equity of CNY 872,628,863.29 by the end of the reporting period[106]. Market and Industry Trends - The company's health supplement segment focuses on the research, production, and sales of food and health food products, with a significant increase in market demand due to changing consumer attitudes post-COVID-19[26]. - The health supplement market in China is projected to grow to CNY 270.8 billion by 2021, driven by a shift from optional to essential consumption[26]. - The elderly population in China is projected to reach 18.7% by 2027, increasing the demand for medical and nursing services[29]. - The health supplement market is experiencing a trend towards younger consumer demographics and diverse consumption scenarios, indicating vast market potential[26]. Research and Development - The company has obtained 34 national patent authorizations, including 9 for probiotic inventions, showcasing its strong R&D capabilities[30]. - Research and development expenses increased by 21.73% to ¥7.08 million, up from ¥5.82 million, reflecting the company's commitment to innovation[36]. - The company emphasizes technological innovation and has increased investment in R&D to maintain its competitive edge in the industry[30]. Operational Highlights - The company operates five self-owned profit-making elderly medical care institutions, generating revenue from medical care, rehabilitation, and catering services[28]. - The occupancy rate of the medical care segment has recovered to pre-pandemic levels, with an overall increase of approximately 1.5% compared to the end of 2020[34]. - The company has established a standardized operational system and strict quality control standards, enhancing its reputation in the industry[32]. Corporate Governance - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[52]. - The company appointed new directors, including Zhao Siyuan, Ma Hebo, and Tang Daoqing, as well as independent directors Li Xia and Qiao Yutuan, during the board election[53]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of 2021, with no dividends or stock bonuses declared[55]. Risks and Challenges - The company faces risks from intensified industry competition, particularly from international enterprises entering the Chinese market and the rise of e-commerce[47]. - The company is at risk of policy changes affecting medical insurance and long-term care insurance, which significantly impact its operational revenue[47]. - Labor costs are a major concern, as the healthcare industry is labor-intensive, with personnel costs comprising a large portion of total operating expenses[47]. Environmental and Social Responsibility - The company undertook energy-saving modifications to its central air conditioning system, expected to save 150 tons of standard coal annually[59]. - The company conducted CCTV and QVU inspections of its rain and sewage pipelines, and upgraded its wastewater treatment facilities[60]. - The company has not disclosed any environmental penalties or issues during the reporting period[57]. Financial Management - The company maintains a stable financial position with no significant debt financing tools in use[81]. - The company plans to continue its focus on enhancing its capital structure and optimizing its financial performance in the upcoming quarters[108]. - The company has allocated resources towards research and development to drive innovation and market expansion[110]. Shareholder Information - The largest shareholder, Dazhong Transportation (Group) Co., Ltd., held 143,184,187 shares, accounting for 18.36% of the total shares[75]. - The company completed a share buyback of 5,080,000 shares, which is 0.6513% of the total share capital, with a total expenditure of RMB 25,006,950[76]. - The company has a total of 34,561 ordinary shareholders at the end of the reporting period[73].

Financial Performance - In 2020, the company achieved a revenue of CNY 332,695,487.68, a slight increase of 0.03% compared to CNY 332,602,654.23 in 2019[20] - The net profit attributable to shareholders was CNY 92,670,121.92, a significant turnaround from a loss of CNY 77,794,294.01 in 2019, representing a 219.12% increase[20] - Basic earnings per share for 2020 were CNY 0.119, compared to a loss of CNY 0.10 in 2019, marking a 219% improvement[21] - The company's total revenue for 2020 was CNY 333 million, a slight increase of 0.03% compared to the previous year[39] - The net profit attributable to shareholders for 2020 was CNY 93 million, representing a significant year-on-year growth of 219.12%[39] - The medical and nursing segment achieved a net profit of CNY 54.7 million in 2020, up from CNY 35.8 million in the previous year[39] - Total operating revenue for the year was CNY 319,255,077.09, an increase of 7.41% compared to the previous year[43] - The company reported a net profit of 4,099.32 million yuan for Horgos Renheng Medical Care Management Co., Ltd., with total assets of 5,217.04 million yuan[72] Assets and Liabilities - The total assets of the company decreased by 8.61% to CNY 1,293,961,078.31 from CNY 1,415,800,418.59 in 2019[20] - Cash and cash equivalents decreased by 35.10% to ¥118,012,055.66 from ¥181,840,564.39 due to loan repayments[52] - Trading financial assets decreased by 55.48% to ¥13,286,110.47 from ¥29,840,202.52 as a result of the disposal of Tai Ling Pharmaceutical[53] - Total liabilities decreased from CNY 623,647,520.87 in 2019 to CNY 421,332,215.02 in 2020, a decrease of approximately 32.5%[164] - Short-term borrowings decreased from CNY 160,000,000.00 in 2019 to CNY 80,000,000.00 in 2020, a 50% decrease[164] - Long-term borrowings decreased from CNY 210,000,000.00 in 2019 to CNY 132,000,000.00 in 2020, a decline of about 37.14%[164] - The company's total equity increased from CNY 792,152,897.72 in 2019 to CNY 872,628,863.29 in 2020, an increase of approximately 10.1%[164] Cash Flow - The company's net cash flow from operating activities was CNY 67,178,715.33, down 32.19% from CNY 99,064,926.35 in 2019[20] - The company experienced a cash flow from operating activities of CNY -9.24 million in Q1, but recovered to CNY 33.85 million in Q2[22] - The net cash flow from operating activities increased significantly to ¥68,606,402.10 in 2020, compared to ¥16,942,429.43 in 2019, representing a growth of approximately 304.5%[179] - The net cash flow from investing activities turned positive at RMB 83,269,976.56, a recovery from a negative cash flow of RMB -250,275,700.60 in 2019[177] Expenses and Costs - Operating costs increased by 25.66% to CNY 191.8 million, compared to CNY 152.6 million in the previous year[40] - Sales expenses decreased by 50.60% to CNY 44 million, down from CNY 89.1 million[40] - Management expenses were reduced by 35.85% to CNY 44.3 million, compared to CNY 69 million in the previous year[40] - Research and development expenses decreased by 28.57% to CNY 12.8 million, down from CNY 17.9 million[40] Market and Business Strategy - The company’s main business includes the R&D, production, and sales of food and health products, as well as the operation and management of elderly medical care institutions[29] - The health product sector is experiencing an upward demand cycle, with significant growth potential driven by government policies promoting health and disease prevention[29] - The company is focusing on digital transformation and innovative business models to adapt to changing consumer behaviors post-COVID-19[29] - The company is focusing on acquiring nursing home projects and disposing of non-operating assets to concentrate on its core business[36] - The aging population in China is projected to continue growing, with over 255 million people aged 60 and above by 2020, highlighting the demand for medical and nursing services[32] Research and Development - The company has developed new probiotic products suitable for diabetes patients and received a patent for the product formula[60] - The company completed major R&D projects, including the development of a solid throat lozenge with cough relief and anti-inflammatory properties[61] - The company is exploring key technologies for high-activity probiotic raw materials applicable to dairy products[61] - The company has made significant investments in R&D, with a focus on improving the viability of lactic acid bacteria and reducing production costs[65] Corporate Governance - The company has a total of 8 independent directors and 5 supervisors, ensuring a robust governance structure[125] - The board of directors consists of 11 members, including 4 independent directors, complying with legal requirements[141] - The company is committed to transparency and compliance with corporate governance standards[131] - The company has established a performance evaluation system linking management compensation to business performance[141] Social Responsibility and Environmental Impact - The company has actively participated in social responsibility activities, including donating RMB 1 million worth of products to medical institutions during the pandemic[101] - The company has invested in environmental protection measures, including upgrading wastewater treatment facilities to reduce COD and BOD levels effectively[102] - The company has not experienced any environmental pollution incidents or received administrative penalties from environmental protection departments during the reporting period[102] Risks and Challenges - The company faces increasing competition from international enterprises entering the Chinese market and the rise of new media and technology applications[78] - The company is exposed to policy risks related to healthcare insurance and long-term care insurance, which could impact its operational stability[78] - The COVID-19 pandemic has affected the occupancy rates and revenue of the company's elderly care institutions, leading to potential declines in revenue and increased operational costs[78]

Financial Performance - Operating revenue rose by 10.67% to CNY 92,854,861.84 year-on-year[7] - Net profit attributable to shareholders decreased by 9.95% to CNY 16,302,514.71 compared to the same period last year[7] - Basic and diluted earnings per share both decreased by 8.70% to CNY 0.021[7] - Total operating revenue for Q1 2021 was CNY 92,854,861.84, an increase of 10.4% compared to CNY 83,907,625.51 in Q1 2020[29] - Net profit for Q1 2021 was CNY 18,876,329.99, a slight increase from CNY 18,454,933.98 in Q1 2020, representing a growth of 2.3%[29] - The net profit attributable to shareholders of the parent company was CNY 16,302,514.71, down from CNY 18,103,106.64 in the previous year, a decrease of 9.9%[30] - The company reported a total comprehensive income of CNY 19,814,419.90 for Q1 2021, compared to CNY 18,464,102.98 in Q1 2020, an increase of 7.3%[30] - The company’s total profit for Q1 2021 was CNY 4,226,170.08, a stark contrast to a total loss of CNY -5,992,281.97 in Q1 2020, indicating a strong recovery trajectory[32] Cash Flow - Net cash flow from operating activities improved significantly, reaching CNY 2,698,588.37, a 129.20% increase from the previous year[7] - The net cash flow from operating activities for the current period was ¥2,698,588.37, a significant increase of 129.20% compared to the previous period's net cash flow of -¥9,242,134.47[17] - The company recorded a total cash inflow from operating activities of CNY 93,325,816.01, an increase from CNY 70,711,771.64 in the previous year, representing a growth of about 32%[33] - Operating cash flow for Q1 2021 was CNY 2,698,588.37, compared to a negative cash flow of CNY -9,242,134.47 in the same period last year, indicating improved operational efficiency[33] - The net cash flow from operating activities for Q1 2021 was ¥24,113,478.24, a decrease from ¥59,535,077.05 in Q1 2020, reflecting a decline of approximately 59.6%[37] Assets and Liabilities - Total assets increased by 5.99% to CNY 1,371,452,232.88 compared to the end of the previous year[7] - Current assets decreased to ¥224,277,876.55 from ¥271,764,441.86 at the end of 2020[20] - The total liabilities as of March 31, 2021, were ¥479,008,949.69, compared to ¥421,332,215.02 at the end of 2020[22] - The company's equity attributable to shareholders increased to ¥852,140,666.31 from ¥834,900,061.69 at the end of 2020[22] - Total liabilities were CNY 372,711,757.72, showing a marginal increase from CNY 371,656,519.68[25] - The total current assets were $315,117,109.13, showcasing liquidity strength[44] Cash and Cash Equivalents - Cash and cash equivalents decreased by 47.12% to CNY 62,408,602.84 due to loan repayments[15] - The company's cash and cash equivalents decreased to ¥62,408,602.84 from ¥118,012,055.66 at the end of 2020[20] - The company's cash and cash equivalents decreased to CNY 295,755,259.68 from CNY 315,117,109.13, a decline of 6.5%[25] - Cash and cash equivalents at the end of Q1 2021 stood at CNY 62,408,602.84, down from CNY 83,679,539.32 at the end of Q1 2020, a decrease of approximately 25%[34] - The cash and cash equivalents at the end of Q1 2021 were ¥6,094,167.03, down from ¥44,038,576.84 at the end of Q1 2020, indicating a decrease of about 86.1%[37] Investment and Financing Activities - The net cash flow from investing activities decreased by 54.71%, amounting to ¥5,267,523.83, down from ¥11,630,203.02 in the previous period[17] - The company’s investment activities generated a net cash inflow of CNY 5,267,523.83 in Q1 2021, compared to CNY 11,630,203.02 in Q1 2020, indicating a decline in investment returns[34] - The net cash flow from financing activities improved by 36.71%, with a current value of -¥63,685,066.66 compared to -¥100,621,417.39 in the previous period[17] - The company’s financing activities resulted in a net cash outflow of CNY -63,685,066.66 in Q1 2021, an improvement from a net outflow of CNY -100,621,417.39 in the same period last year[34] Cost Management - The company reported a decrease in management expenses due to reduced consulting fees, contributing to overall cost management[18] - Total operating costs decreased to CNY 79,791,326.54 from CNY 80,764,798.72, reflecting a reduction of 1.2%[29] - Research and development expenses for Q1 2021 were CNY 3,267,947.35, slightly down from CNY 3,348,068.21 in the previous year[29]

Financial Performance - Net profit attributable to shareholders decreased by 41.34% year-on-year, totaling RMB 54,561,006.53 for the first nine months[8] - Operating income increased by 2.11% year-on-year, reaching RMB 251,914,780.47 for the first nine months[8] - Basic earnings per share decreased by 41.18% to RMB 0.070[8] - Total revenue for Q3 2020 was CNY 95,466,803.66, a decrease of 13.7% compared to CNY 110,610,787.34 in Q3 2019[32] - The company's net loss for Q3 2020 was CNY 3,123,306.41, compared to a loss of CNY 305,171.28 in Q3 2019[32] - The company's operating profit for Q3 2020 was ¥-10,130,194.16, compared to an operating profit of ¥9,208,348.79 in Q3 2019, marking a decline of 209.8%[36] - The total profit for Q3 2020 was ¥-9,565,442.27, down from ¥9,206,548.79 in Q3 2019, reflecting a decrease of 204.3%[36] - The total comprehensive income for Q3 2020 was ¥29,338,863.46, compared to ¥31,885,455.43 in Q3 2019, a decrease of approximately 7.9%[34] Asset and Liability Changes - Total assets decreased by 7.47% year-on-year, amounting to RMB 1,310,007,223.72 at the end of the reporting period[8] - Total assets decreased to ¥1,310,007,223.72 from ¥1,415,800,418.59, reflecting a decline in both current and non-current assets[27] - Total liabilities decreased to CNY 439,763,668.38 from CNY 623,951,371.70 year-over-year[31] - The total assets as of the end of Q3 2020 amounted to ¥1,415,800,418.59, with total liabilities at ¥623,647,520.87, resulting in total equity of ¥792,152,897.72[49] - The company’s retained earnings showed a deficit of -¥223,383,329.91, indicating challenges in profitability[49] Cash Flow and Financial Health - The net cash flow from operating activities decreased by 36.47% year-on-year, amounting to RMB 35,663,404.09[8] - Cash and cash equivalents decreased by 35.32% year-on-year, totaling RMB 117,611,101.44[14] - The net cash flow from operating activities for the first three quarters of 2020 was ¥35,663,404.09, a decrease of 36.5% compared to ¥56,133,052.50 in the same period of 2019[41] - Total cash inflow from operating activities was ¥261,496,412.21, down from ¥319,193,209.98 in the previous year, reflecting a decline of 18.1%[41] - The company incurred cash outflows of ¥225,833,008.12 from operating activities, down from ¥263,060,157.48 in the same period of 2019[41] - The total cash outflow from financing activities was ¥189,196,439.61, compared to ¥260,457,268.93 in the previous year, indicating a reduction of 27.3%[42] Expense Management - Operating costs rose to ¥128,340,449.63, reflecting a significant increase of 15.55% from ¥111,072,880.32 in the prior period, primarily due to increased costs in the pharmaceutical sector[17] - Sales expenses decreased by 23.41% to ¥40,546,554.10 from ¥52,937,954.69, attributed to better cost control measures[17] - Financial expenses surged by 110.69% to ¥4,868,739.56, up from ¥2,310,829.46, mainly due to increased borrowing interest[17] - R&D expenses decreased by 42.46% to ¥8,316,124.31 from ¥14,453,646.89, indicating a reduction in investment in research and development[17] - Research and development expenses for Q3 2020 were CNY 2,495,855.31, down from CNY 4,205,907.97 in Q3 2019[32] Shareholder Information - The number of shareholders reached 29,695 at the end of the reporting period[12] - The total equity attributable to shareholders increased to CNY 793,554,089.14 from CNY 752,585,076.34 year-over-year[30] - Basic and diluted earnings per share for the third quarter were both -¥0.012, compared to ¥0.015 in the same quarter of 2019[38]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥156,449,097.57, representing a 12.92% increase compared to ¥138,550,219.06 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 58.43% to ¥30,635,518.42 from ¥73,703,028.64 in the previous year[19]. - The net profit after deducting non-recurring gains and losses increased significantly by 339.71% to ¥10,333,409.12 from ¥2,350,049.39 in the same period last year[19]. - The net cash flow from operating activities was ¥24,610,520.33, down 20.86% from ¥31,097,355.26 in the previous year[19]. - Basic earnings per share decreased by 58.51% to ¥0.039 from ¥0.094 in the same period last year[20]. - The weighted average return on net assets decreased by 3.77 percentage points to 4.05% from 7.82% in the previous year[20]. - The company reported a net loss of ¥192,747,811.49, an improvement from a loss of ¥223,383,329.91 in the previous period[89]. - The net profit for the first half of 2020 was ¥31,946,415.49, down from ¥74,122,020.60 in the first half of 2019, indicating a decline of about 56.9%[96]. - The company's basic earnings per share for the first half of 2020 was ¥0.039, compared to ¥0.094 in the same period of 2019, a decrease of approximately 58.5%[97]. Assets and Liabilities - The total assets decreased by 7.53% to ¥1,309,198,152.28 from ¥1,415,800,418.59 at the end of the previous year[19]. - Current assets totaled ¥272,576,719.22, down from ¥375,796,461.48, indicating a decrease of about 27.5%[88]. - Cash and cash equivalents decreased to ¥116,239,481.92 from ¥181,840,564.39, representing a decline of approximately 36.1%[87]. - Total liabilities decreased to ¥502,553,674.44 from ¥623,647,520.87, a reduction of about 19.4%[89]. - Short-term borrowings decreased significantly to ¥80,000,000.00 from ¥160,000,000.00, a decrease of 50%[88]. - Long-term borrowings decreased to ¥183,750,000.00 from ¥210,000,000.00, reflecting a decline of approximately 12.6%[89]. Market and Business Operations - The company's main business includes the R&D, production, and sales of food and health food products, as well as the operation and management of elderly medical care institutions[24]. - The health product segment has seen a market scale growth, reaching approximately RMB 222.7 billion in 2019, with expectations to exceed RMB 330 billion by 2021[26]. - The elderly care market is expanding due to an aging population, with 25.39 million people aged 60 and above in China by the end of 2019, representing 18.1% of the population[28]. - The company operates 6 self-owned profit-making elderly medical care institutions, generating revenue from medical care, drug sales, and meal services[28]. - The company has established a strong brand presence with trademarks like "昂立," recognized as a "China Famous Trademark" and a top brand in the health product sector[30]. - The company has a significant scale advantage in the elderly care sector, with a leading number of care beds in the industry[31]. Cost Management and Expenses - The operating costs increased by 31.71% to approximately ¥83.09 million, primarily due to the growth in the healthcare segment[40]. - Sales expenses decreased by 22.30% to approximately ¥30.31 million, while management expenses were reduced by 23.00% to approximately ¥21.66 million[40]. - The company has implemented a structured cost management system to analyze operational costs across various levels, enhancing cost control capabilities[31]. Research and Development - The company launched several new probiotic products targeting specific demographics, including a solid beverage for urban young women and a DHA algae oil powder for children, expected to hit the market between late 2020 and early 2021[33]. - Research and development expenses amounted to ¥5,820,269.00, significantly lower than ¥10,247,738.92 in the first half of 2019, indicating a reduction of approximately 43.5%[95]. Shareholder and Equity Information - The company’s major shareholder, Zhongjin Group, increased its stake by acquiring 7,800,600 shares, representing 1.00% of the total share capital at an average price of 3.10 CNY per share[54]. - The total number of ordinary shareholders as of the end of the reporting period is 34,196[74]. - The top ten shareholders hold a total of 18.36% (143,184,187 shares) of the company's shares[77]. - The company’s total equity decreased from ¥1,197,453,882.20 to ¥1,179,500,940.50, a decline of approximately 1.5%[93]. Environmental and Regulatory Compliance - The company has implemented various environmental protection measures, including biochemical treatment for wastewater and odor removal systems[68]. - The company has not experienced any environmental pollution incidents or received administrative penalties from environmental protection departments during the reporting period[68]. Future Outlook and Strategic Plans - The company plans to enhance its brand presence through targeted marketing campaigns, achieving a media reach of 410 million during the Spring Festival advertising[33]. - The company anticipates that the slowdown in existing business growth and delays in new institution openings will impact the performance commitments for 2020-2021[52]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[110]. Financial Reporting and Accounting Policies - The company’s financial statements are prepared based on the assumption of going concern, indicating no significant doubts about its ability to continue operations[123]. - The company implemented new accounting policies effective January 1, 2020, including the new revenue recognition standard and new lease accounting standard[194]. - The company recognizes expected liabilities when there is a present obligation that is likely to result in an outflow of economic benefits[182].

Financial Performance - Operating revenue increased by 6.96% year-on-year, reaching CNY 83,905,629.95[5] - Net profit attributable to shareholders decreased by 76.42%, totaling CNY 18,103,106.64[5] - Basic earnings per share dropped by 76.53% to CNY 0.023[5] - The weighted average return on equity decreased by 2.32 percentage points to 2.38%[5] - Total operating revenue for Q1 2020 was CNY 83,907,625.51, an increase of 3.3% compared to CNY 80,276,144.62 in Q1 2019[30] - Net profit attributable to shareholders for Q1 2020 was CNY 18,103,106.64, a decrease of 76.4% from CNY 76,783,603.67 in Q1 2019[31] - Basic earnings per share for Q1 2020 were CNY 0.023, down from CNY 0.098 in Q1 2019[31] - In Q1 2020, the company reported a net profit of -5,992,281.97 RMB, compared to a net profit of 69,107,415.07 RMB in Q1 2019, indicating a significant decline[33] - The total comprehensive income for Q1 2020 was -5,992,281.97 RMB, compared to -13,471,318.07 RMB in Q1 2019, indicating a reduced loss[33] Asset and Liability Changes - Total assets decreased by 6.11% from the previous year, amounting to CNY 1,415,800,418.59[5] - Total assets decreased from ¥1,415,800,418.59 to ¥1,329,304,349.70, reflecting a reduction in current assets[22] - The company reported a total asset of CNY 1,723,275,753.55 as of Q1 2020, down from CNY 1,821,405,253.90 in Q1 2019[27] - Total liabilities decreased to CNY 547,861,106.82 in Q1 2020 from CNY 623,951,371.70 in Q1 2019, reflecting a reduction of 12.2%[27] - The company’s total equity decreased to CNY 1,175,414,646.73 in Q1 2020 from CNY 1,197,453,882.20 in Q1 2019[27] Cash Flow Analysis - Cash flow from operating activities improved by 55.24%, amounting to CNY -9,242,134.47[5] - Net cash flow from operating activities improved by 55.24% to -¥9,242,134.47 compared to -¥20,650,456.60 in the previous period[20] - The net cash flow from operating activities was $59,535,077.05, a significant improvement compared to a net outflow of $12,861,163.79 in the previous year[38] - Total cash outflow from operating activities amounted to $51,291,007.04, up from $31,000,749.25 year-over-year[38] - The ending cash and cash equivalents balance was $44,038,576.84, a decrease from $369,451,138.87 year-over-year[38] Expense and Income Changes - Operating costs rose by 27.26% compared to the previous period, totaling CNY 45,329,446.42[15] - Management expenses increased by 34.22% to ¥12,844,304.75 due to the addition of the healthcare segment[16] - Financial expenses decreased by 39.06% to ¥3,695,149.12 as a result of reduced foreign exchange losses[16] - Other income surged by 54,710.14% to ¥1,822,853.65 primarily from government subsidies received[16] - Investment income dropped by 82.53% to ¥16,788,969.86 due to the disposal of Industrial Securities in the previous period[16] - Credit impairment losses decreased by 97.77% to ¥42,710.58 as receivables remained within the payment period[17] - Income tax expenses fell by 85.61% to ¥3,323,322.20 due to tax provisions related to the disposal of Industrial Securities in the previous period[17] - The company incurred financial expenses of 4,183,136.68 RMB in Q1 2020, compared to 1,815,418.04 RMB in Q1 2019, reflecting an increase of 130.5%[33] - The company paid $8,761,298.81 in employee compensation and related cash payments, compared to $11,768,748.74 in the previous year[38] - The company incurred tax payments of $311,097.91, significantly lower than $2,007,663.78 in the previous year[38] Shareholder Information - The number of shareholders reached 40,108 at the end of the reporting period[11] - The company repurchased 5,080,000 shares, accounting for 0.6513% of the total share capital[19] Investment Activities - Net cash flow from investing activities decreased by 96.25% to ¥11,630,203.02 due to the previous period's disposal of Industrial Securities[20] - The total cash inflow from investing activities was $324,465,324.56, while cash outflow was $12,970,606.04[38]

Financial Performance - In 2019, the company's operating revenue was CNY 332,602,654.23, an increase of 33.56% compared to CNY 249,037,021.14 in 2018[21] - The net profit attributable to shareholders was a loss of CNY 77,794,294.01, improving by 84.63% from a loss of CNY 506,039,123.53 in 2018[21] - The net cash flow from operating activities was CNY 99,064,926.35, a significant increase of 694.20% compared to CNY 12,473,573.61 in 2018[21] - The total assets at the end of 2019 were CNY 1,415,800,418.59, a decrease of 1.25% from CNY 1,433,752,750.98 at the end of 2018[21] - The basic earnings per share for 2019 was -CNY 0.10, an improvement of 84.59% from -CNY 0.649 in 2018[22] - The weighted average return on equity was -8.98%, an increase of 30.64 percentage points from -39.62% in 2018[23] - The company reported a net asset attributable to shareholders of CNY 752,585,076.34 at the end of 2019, a decrease of 16.68% from CNY 903,233,601.57 at the end of 2018[21] - The company faced a delisting risk due to consecutive years of negative net profit attributable to shareholders[6] Revenue and Profit Trends - In Q1, the company reported revenue of approximately ¥78.44 million, while in Q2, revenue decreased to about ¥60.11 million, followed by an increase to ¥108.15 million in Q3, and a decline to ¥85.90 million in Q4[24] - The net profit attributable to shareholders was ¥76.78 million in Q1, but turned negative in Q2 with a loss of ¥3.08 million, followed by a profit of ¥19.30 million in Q3, and a significant loss of ¥170.80 million in Q4[24] - The company’s total revenue for 2019 was CNY 332.6 million, representing a year-on-year increase of 33.56%[41] - The net profit attributable to shareholders was CNY -78 million, showing a year-on-year growth of 84.63% due to the disposal of long-term equity investments[41] Operational Developments - The company operates six self-owned profit-making elderly care institutions, generating revenue from medical care, drug sales, and meal services, with costs including rent and employee salaries[32] - The company has completed construction of three new elderly care facilities, with one already in trial operation[39] - The average occupancy rate of the newly acquired Shanghai Renxing increased from 83.5% to 86.3% during the reporting period[39] - The company is focused on expanding its elderly care services and management consulting for non-profit institutions, indicating a strategic move towards the aging population market[32] Research and Development - The company’s R&D expenses increased by 13.94% to CNY 17.9 million, reflecting a focus on product development[43] - Research and development expenses totaled CNY 17,854,979.71, accounting for 5.37% of total revenue, with 51 R&D personnel representing 5.5% of the total workforce[52] - The company plans to continue R&D on probiotic strains and production processes, with 5 new terminal products to be developed in the upcoming year[73] Market and Industry Insights - The company’s health supplement segment is experiencing growth, with the Chinese health supplement market reaching ¥257.5 billion in 2018, reflecting an 8.4% year-on-year increase[31] - The health food market in China reached ¥257.5 billion, with an expected growth of 8.4% year-on-year[60] - The elderly care industry is projected to face a shortfall of 4 million beds by 2030, indicating a significant market opportunity[61] Corporate Governance and Compliance - The company has adhered to the revised financial reporting formats issued by the Ministry of Finance in 2019, ensuring compliance with updated accounting standards[98] - The company engaged Lixin Accounting Firm for auditing services, with a remuneration of 1,000,000 RMB for the audit period[101] - The company has established a risk management system to address various risks, including compliance, labor, and fire hazards, with performance management linked to risk management outcomes[85] Shareholder and Equity Information - The company did not distribute any dividends in 2019, 2018, and 2017, with a cash dividend amount of 50,700,000 RMB in 2017, representing 31.60% of the net profit attributable to ordinary shareholders[93] - The total guarantee amount provided by the company, including guarantees to subsidiaries, was 140 million RMB for short-term loans and 230 million RMB for long-term loans as of December 31, 2019[109] - The total number of ordinary shares and the share capital structure remained unchanged during the reporting period[120] Financial Position and Cash Flow - The company reported a significant increase in cash received from sales, totaling CNY 343,363,080.75 in 2019, compared to CNY 294,292,957.21 in 2018[190] - The total cash and cash equivalents at the end of 2019 were CNY 181,782,564.39, down from CNY 220,562,894.99 at the end of 2018[192] - The company experienced a net decrease in cash and cash equivalents of CNY -38,780,330.60 for the year 2019[192] Challenges and Risks - The COVID-19 pandemic has impacted sales and production, with strict controls on new resident admissions in elderly care facilities affecting occupancy rates[88] - The company faces risks including potential delisting due to negative net profits for two consecutive years, which could trigger warnings under the Shanghai Stock Exchange rules[87] - The company has faced challenges with non-recurring losses, including a loss of ¥92.64 million from non-current asset disposals in 2019[26]

Financial Performance - Net profit attributable to shareholders rose by 12.16% to RMB 93,005,042.87 for the first nine months[7] - Operating revenue for the first nine months increased by 27.25% to RMB 246,701,778.16 compared to the same period last year[7] - The company reported a net loss of ¥49,315,535.92 for the period, an improvement from a loss of ¥228,112,625.96 in the previous period[24] - Net profit for Q3 2019 was ¥27,288,928.41, compared to ¥18,916,771.10 in Q3 2018, marking an increase of 43.5%[29] - The company achieved an investment income of ¥93,044,463.69 for the first three quarters of 2019, compared to ¥94,209,267.01 in the same period of 2018[29] - The total comprehensive income for Q3 2019 was ¥31,885,455.43, compared to ¥18,916,771.10 in Q3 2018, indicating a growth of 68.4%[30] Assets and Liabilities - Total assets increased by 21.04% year-on-year, reaching RMB 1,735,467,120.40[7] - The company reported a significant increase in accounts receivable, which rose by 112.27% to RMB 79,709,884.68[12] - The company’s long-term equity investments increased by 11.26% to RMB 396,201,506.83[12] - Total liabilities reached ¥690,990,040.12, up from ¥450,680,217.13, marking an increase of approximately 53.2%[24] - Non-current liabilities rose significantly to ¥270,144,731.88 from ¥34,438,319.73, indicating an increase of over 684%[24] - The total assets and shareholders' equity amounted to ¥1,984,982,227.59 and ¥1,309,499,143.70 respectively, reflecting a year-on-year increase of 15.6% and 4.1%[28] Cash Flow - The net cash flow from operating activities improved significantly, showing a net inflow of RMB 56,133,052.50, a 496.18% increase year-on-year[7] - The net cash flow from investing activities decreased by 668.13% to -¥299,879,347.44, mainly due to the payment of ¥600,000,000 for the acquisition[19] - The company reported a net cash flow from operating activities of CNY 56,133,052.50 for the first three quarters of 2019, a significant improvement from a net outflow of CNY 14,168,719.21 in the same period of 2018[36] - The net cash flow from financing activities was 247,022,731.07 RMB, a substantial increase from 17,443,390.41 RMB in the previous year[39] - The total cash outflow from investment activities was 620,216,971.88 RMB, compared to 53,470,778.03 RMB in Q3 2018, reflecting aggressive investment strategies[39] Shareholder Information - The number of shareholders reached 42,015, with the top ten shareholders holding a combined 66.88% of shares[10] - The company has not yet repurchased shares as part of its share buyback plan initiated earlier in the year[20] Research and Development - Research and development expenses increased by 41.11% to ¥14,453,646.89, reflecting a higher investment in R&D[17] - Research and development expenses for the first three quarters of 2019 were ¥14,453,646.89, up from ¥10,242,943.62 in the same period of 2018, indicating a growth of 41.5%[28] - Research and development expenses in Q3 2019 amounted to CNY 3,174,999.96, up 54.4% from CNY 2,056,738.77 in Q3 2018[33] Acquisitions - The company completed the acquisition of 100% of Shanghai Renxing, impacting various financial metrics including goodwill and intangible assets[18] - The company reported an increase in accounts receivable due to the consolidation of Shanghai Renxing's receivables[14] - Deferred tax liabilities increased due to the valuation surplus from the acquisition of Shanghai Renxing[15] Financial Ratios - The weighted average return on equity increased by 4.55 percentage points to 9.76%[7] - Basic earnings per share for Q3 2019 were ¥0.025, slightly up from ¥0.024 in Q3 2018[30] - The total operating profit for the first three quarters of 2019 was CNY 84,209,675.29, compared to CNY 77,404,463.13 in the same period of 2018, reflecting a growth of 8.0%[33]

Financial Performance - The company's operating revenue for the first half of 2019 was ¥138,550,219.06, a decrease of 4.87% compared to ¥145,645,882.47 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥73,703,028.64, an increase of 14.48% from ¥64,381,470.28 year-on-year[19]. - The total profit reached 94.82 million yuan, reflecting a year-on-year increase of 16.65%[32]. - The company reported a significant decrease of 87.19% in net profit after deducting non-recurring gains and losses, amounting to ¥2,350,049.39 compared to ¥18,339,757.87 in the previous year[19]. - The company achieved total revenue of 142.59 million yuan, a year-on-year decrease of 5.00%[32]. - The basic earnings per share for the first half of 2019 were ¥0.094, up 13.25% from ¥0.083 in the same period last year[20]. - The total comprehensive income for the first half of 2019 was CNY 74,122,020.60, compared to a loss of CNY 77,219,194.22 in the same period of 2018[87]. - The company reported a net loss of RMB 68,617,550.15 for the first half of 2019, an improvement compared to a net loss of RMB 228,112,625.96 in the same period of the previous year[80]. Cash Flow and Investments - The net cash flow from operating activities was ¥31,097,355.26, a significant improvement from a negative cash flow of ¥27,700,748.54 in the previous year[19]. - Cash inflows from operating activities totaled CNY 213,598,084.20, an increase from CNY 187,795,714.78 in the same period of 2018[93]. - The company reported a significant increase in cash received from investment recoveries, amounting to 323,966,286.81 RMB, compared to 107,735,252.68 RMB in the same period last year[96]. - The company incurred total cash outflows from financing activities of 194,884,659.19 RMB, compared to 227,459,268.48 RMB in the same period last year, reflecting a decrease of about 14%[94]. - The net cash flow from investment activities was -49,881,394.66 RMB, a decline from a positive cash flow of 55,777,336.08 RMB in the prior year[94]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,727,403,686.47, representing a 20.48% increase from ¥1,433,752,750.98 at the end of the previous year[19]. - The total liabilities increased to RMB 699,210,981.61 from RMB 450,680,217.13 at the end of 2018, indicating a significant rise in financial obligations[80]. - The company's current assets decreased to RMB 332,581,534.91 from RMB 339,824,728.64 at the end of 2018, primarily due to a reduction in cash and cash equivalents[79]. - The company's total liabilities increased to CNY 682,193,883.03 from CNY 458,284,248.96, marking a rise of 48.9%[84]. - The company's equity attributable to shareholders rose to RMB 979,587,712.48 from RMB 903,233,601.57 at the end of 2018, reflecting improved shareholder value[80]. Strategic Initiatives - The company is focusing on the acquisition of elderly care institutions and the disposal of non-operating assets to concentrate on core business development[32]. - The company has strengthened market planning by launching the Angli Health brand strategy and upgrading its visual identity[32]. - New product development has been accelerated, with strict quality control measures implemented[32]. - The company has completed the relocation of its new production base and is in the process of trial production for some production lines[32]. - The company has established a strong competitive edge in the probiotic sector, holding 8 authorized invention patents and 21 strains of proprietary probiotics[29]. Shareholder Information - The total number of ordinary shareholders as of the reporting period end was 46,068[70]. - The top ten shareholders held a total of 413,000,000 shares, representing 51.82% of the total shares[72]. - The largest shareholder, Dazhong Transportation Group, held 143,184,187 shares, accounting for 18.36% of the total shares[72]. Compliance and Governance - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[6]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[7]. - The company has not yet repurchased shares despite announcing a buyback plan on January 30, 2019[50]. - The company has not reported any major litigation or arbitration matters during the reporting period[58]. - The company has fulfilled all commitments made by its actual controllers and shareholders during the reporting period[56]. Research and Development - Research and development expenses increased by 45.01% to ¥10,247,738.92, up from ¥7,066,741.52 in the previous year[35]. - The company has invested approximately 70 million RMB to establish a new production facility in Songjiang District, Shanghai, which has been completed by the reporting period[44]. - The company obtained production licenses for several products, including protein solid beverages and probiotics, with some production lines already in operation[50]. Risk Factors - The company faces risks related to product quality, industry policies, rising labor costs, and potential defaults on loans due to economic conditions[48][49]. - The company has not disclosed any significant changes in accounting policies or estimates during the reporting period[67]. - The company has not reported any major contract performance issues during the reporting period[65].